Balanced news tone
News Sentiment
GOVX sentiment intelligence
GeoVax Labs Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
49
Balanced news tone
61 relevant articles
Price is moving more forcefully than the current news tone suggests.
85/100 classification confidence.
directly relevant articles
high-authority source matches
-17.4% over one week, -27.3% over four weeks, trend inactive, and below fair value.
GeoVax Highlights Strategic Alignment of GEO-MVA With HHS/ASPR's Five-Year Medical Countermeasure Preparedness Strategy
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
85/100 classification
One-week reaction
-17.4%
Price reacting lower
Trend fit
Trend inactive
-27.3% over four weeks
Fair value
-98.3%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
6
Neutral
45
Negative
10
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
NewMediaWire
Direct company coverage
GeoVax Highlights Strategic Alignment of GEO-MVA With HHS/ASPR's Five-Year Medical Countermeasure Preparedness Strategy
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jul 2026 13:00
- Source
- NewMediaWire
Market source
Industry context
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 18:49
- Source
- Market source
Moomoo
Direct company coverage
GeoVax Labs(GOVX) Stock Options Chain | Quotes & News
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 12:07
- Source
- Moomoo
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 07:00
- Source
- Market source
The Globe and Mail
Direct company coverage
GeoVax Labs Faces Nasdaq Noncompliance and Listing Risk
GeoVax Labs has received a notice from Nasdaq regarding noncompliance with its minimum stockholders' equity requirement, potentially leading to delisting. The company has 45 days to submit a compliance plan. This situation highlights GeoVax's financial strain and introduces uncer
- Tone
- Negative 18/100
- Event
- Market update
- Published
- 12 Jul 2026 17:09
- Source
- The Globe and Mail
Moomoo
Direct company coverage
GeoVax Labs | 8-K: Current report
This document is an 8-K current report filed by GeoVax Labs with the SEC. It indicates that the full text of the report is available via a direct link to the SEC filing, and users may need to accept cookies to view it.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jul 2026 17:11
- Source
- Moomoo
ChartMill
Direct company coverage
GEOVAX LABS INC (GOVX) Stock Chart
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jul 2026 00:06
- Source
- ChartMill
TradingView
Direct company coverage
GeoVax Labs Received Notice of Noncompliance
GeoVax Labs (GOVX) received a notice from Nasdaq on July 7, 2026, indicating noncompliance with the minimum stockholders' equity requirement of $2,500,000. The company has 45 days, until August 21, 2026, to submit a compliance plan. Trading of GOVX shares continues on Nasdaq.
- Tone
- Negative 29/100
- Event
- Market update
- Published
- 10 Jul 2026 20:41
- Source
- TradingView
Stock Titan
Direct company coverage
GeoVax Labs (NASDAQ: GOVX) flagged for Nasdaq $2.5M equity shortfall, delisting risk
GeoVax Labs (NASDAQ: GOVX) received a notice from Nasdaq on July 7, 2026, indicating non-compliance with the $2.5 million minimum stockholders’ equity requirement and alternative standards. The company has 45 calendar days, until August 21, 2026, to submit a compliance plan, with
- Tone
- Negative 10/100
- Event
- Market update
- Published
- 10 Jul 2026 19:41
- Source
- Stock Titan
Moomoo
Direct company coverage
GeoVax Labs (GOVX) Stock Forecast & Analyst Ratings
This article provides a stock forecast and analyst ratings for GeoVax Labs (GOVX). It includes information on the general consensus among analysts, price targets, and potential future performance of the company's stock.
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 09 Jul 2026 03:41
- Source
- Moomoo
Market source
Direct company coverage
GeoVax Highlights Continued U.S. Government Investment in Orthopox Preparedness as Strategic Validation of Long-Term Vaccine Readiness
GeoVax Labs, Inc. commented on the U.S. government's recent procurement of additional ACAM2000(R) smallpox vaccine, interpreting it as ongoing strategic validation of long-term vaccine readiness and investment in orthopoxvirus preparedness. The company views this continued federa
- Tone
- Positive 75/100
- Event
- Market update
- Published
- 02 Jul 2026 01:12
- Source
- Market source
TradingView
Direct company coverage
Price to earnings forward of GeoVax Labs, Inc. – NASDAQ:GOVX
This page from TradingView provides financial information for GeoVax Labs, Inc. (NASDAQ: GOVX), specifically focusing on its price-to-earnings forward metric. The content appears to be a financial data presentation rather than an analytical article, showing market data and naviga
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 01 Jul 2026 18:08
- Source
- TradingView
Market source
Direct company coverage
GeoVax Labs (GOVX) Stock Fair Value Moves Lower After Pipeline Shift
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 27 Jun 2026 07:00
- Source
- Market source
TradingView
Direct company coverage
GeoVax Labs, Inc. Actuals & Estimates (NASDAQ:GOVX)
This article provides an overview of GeoVax Labs, Inc. (NASDAQ: GOVX) stock, including its current price, market capitalization, and historical performance. It also details analyst forecasts, past earnings, and upcoming financial reporting dates for the biotechnology company. The
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 10:39
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of GeoVax Labs, Inc. – NASDAQ:GOVX
This article provides financial data for GeoVax Labs, Inc. (NASDAQ: GOVX), specifically focusing on its forward price-to-sales ratio. It indicates that the company's financial information, including period value, change, and percentage change, is available, likely through the Tra
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 03:42
- Source
- TradingView
Stock Titan
Direct company coverage
[Form 4] GeoVax Labs, Inc. Insider Trading Activity
GeoVax Labs, Inc. reported insider trading activity where Chief Medical Officer Kelly T. McKee Jr. received a grant of 17,600 stock options, exercisable at $1.18 per share. These options vest in three equal annual installments and expire on June 17, 2036. Following this transacti
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Jun 2026 12:40
- Source
- Stock Titan
Investing.com South Africa
Direct company coverage
Form 4 GeoVax Labs Inc For: 22 June By Investing.com
This article from Investing.com simply announces a Form 4 filing for GeoVax Labs Inc. on June 22nd. It does not provide any further details about the content of the filing or its implications. The article primarily consists of navigational elements and market data, typical of a f
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 10:10
- Source
- Investing.com South Africa
Stock Titan
Direct company coverage
Director at GeoVax (GOVX) receives 6,000-share stock option grant
GeoVax Labs, Inc. director Randal D. Chase was granted 6,000 stock options with an exercise price of $1.18 per share. These options become exercisable on June 17, 2027, and will expire on June 17, 2036. This transaction is a grant and not an open-market purchase or sale of existi
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 10:10
- Source
- Stock Titan
Stock Titan
Direct company coverage
GeoVax Labs (GOVX) CFO awarded 17,600 stock options in new grant
GeoVax Labs' CFO, Mark Reynolds, was granted 17,600 stock options with an exercise price of $1.18 per share. These options, expiring on June 17, 2036, will become exercisable in three equal annual installments on the first three anniversaries of the grant date, as reported in a F
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 09:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
GeoVax (GOVX) director awarded 6,000 stock options at $1.18 strike
GeoVax Labs, Inc. director Robert T. McNally was granted 6,000 stock options with an exercise price of $1.18 per share. These options become exercisable on June 17, 2027, and have an expiration date of June 17, 2036. This transaction was a compensation-related award and not an op
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 09:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
GeoVax (GOVX) director awarded 6,000 stock options at $1.18 exercise price
GeoVax Labs, Inc. director Morgan Jayne was granted 6,000 stock options with an exercise price of $1.18 per share. These options become exercisable on June 17, 2027, and are set to expire on June 17, 2036. This transaction is categorized as a compensation-related award of derivat
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 22:10
- Source
- Stock Titan
Stock Titan
Direct company coverage
GeoVax (GOVX) director receives 6,000 stock options at $1.18 strike
GeoVax Labs, Inc. director John N. Spencer Jr has been granted 6,000 stock options with an exercise price of $1.18 per share. These options become exercisable on June 17, 2027, and have an expiration date of June 17, 2036. This transaction is categorized as an acquisition of deri
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 22 Jun 2026 22:10
- Source
- Stock Titan
Stock Titan
Direct company coverage
GeoVax Labs (GOVX) director gets grant of 6,000 stock options
GeoVax Labs director Dean G. Kollintzas was granted 6,000 stock options on June 17, 2026. These options have an exercise price of $1.18 per share and expire on June 17, 2036. This transaction is categorized as a compensation-related award, not a market purchase, increasing his de
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 21:40
- Source
- Stock Titan
Stock Titan
Direct company coverage
GeoVax (GOVX) CEO David Dodd granted 29,300 stock options at $1.18 strike
GeoVax Labs, Inc. President and CEO David A. Dodd was granted 29,300 stock options with an exercise price of $1.18 per share. These options, which expire on June 17, 2036, will vest in three equal annual installments on the first three anniversaries of the grant date. This transa
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 20:10
- Source
- Stock Titan
Stock Titan
Direct company coverage
GeoVax Labs (GOVX) VP receives grant of 17,600 stock options
GeoVax Labs, Inc. (GOVX) VP of Business Development, John W. Sharkey, received a grant of 17,600 stock options on June 17, 2026. These options have an exercise price of $1.18 per share and will vest in three equal annual installments, expiring on June 17, 2036. This transaction i
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 20:10
- Source
- Stock Titan
Stock Titan
Direct company coverage
Director at GeoVax Labs (NASDAQ: GOVX) granted 6,000 options
GeoVax Labs director Nicole Lemerond was granted 6,000 stock options, which allow her to purchase common stock at an exercise price of $1.18 per share, with an expiration date of June 17, 2036. This transaction is classified as a routine equity compensation award, not an open-mar
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 20:10
- Source
- Stock Titan
TradingKey
Direct company coverage
GeoVax Labs Inc (GOVX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey attempts to provide a revenue breakdown for GeoVax Labs Inc (GOVX) by business segments and regions. However, it explicitly states that the relevant financial data has not yet been disclosed by the company, making a detailed analysis impossible at thi
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 19:39
- Source
- TradingKey
TradingKey
Direct company coverage
GeoVax Labs Inc (GOVX) Institutional Confidence
This article provides an overview of institutional confidence in GeoVax Labs Inc (GOVX), highlighting key shareholders and their holdings. The company's stock information, including its recent price and market capitalization, is also presented, alongside a breakdown of various fi
- Tone
- Positive 75/100
- Event
- Market update
- Published
- 18 Jun 2026 19:39
- Source
- TradingKey
TradingKey
Direct company coverage
GeoVax Labs Inc (GOVX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides an overview of GeoVax Labs Inc.'s (GOVX) shareholder structure, detailing major institutional shareholders and their holdings. It lists top shareholders like Citadel Advisors LLC and Renaissance Technologies LLC, along with various shareholder types and thei
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 03:09
- Source
- TradingKey
TradingKey
Direct company coverage
GeoVax Labs Inc (GOVX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of GeoVax Labs Inc (GOVX) dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years and lists several stock merger events from January 2024 and one scheduled for January 2026. The data
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 18 Jun 2026 02:09
- Source
- TradingKey